Mohamad Sadek Zoghbi

Dr. Mohamad Sadek Zoghbi

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2026 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
MZMohamad Sadek Zoghbi
Mohamad Sadek Zoghbi
AFAdnan Fatfat
Adnan Fatfat
DJDiala Jazra
Diala Jazra
EBElio Bitar
Elio Bitar
KEKarine Eid
Karine Eid
SASalim Adib
Salim Adib
The spread of medical misinformation through conventional and online communication poses a public health risk, especially in countries like Lebanon, where the healthcare system is fragile. Its dangers were highlighted during the COVID-19 pandemic and other health emergencies, showing how inaccurate or misleading information can alter public health behavior. Despite growing awareness about the problem, no study in Lebanon has explored health misinformation from the perspective of key healthcare stakeholders. The aim of this study was to investigate the views of key stakeholders on the causes and implications of health-related misinformation in Lebanese media, and to provide recommendations to combat it. We conducted a qualitative study using semi-structured, in-depth interviews with nine elite interviewees from the media, health sector, government, professional syndicates, and legal system. Interviews were conducted between March 17 and 25, 2025 and thematically analyzed using an inductive-deductive approach. Data saturation was reached at the eighth interview. Trustworthiness was ascertained through triangulated coding, reflexivity, and adherence to established qualitative rigor criteria. Factors contributing to the spread of health misinformation included low health literacy, poverty, political pressure on the media, and a lack of regulations on digital platforms. WhatsApp, Facebook, and Instagram were identified as major channels for rapid dissemination. Although some Lebanese media outlets practiced voluntary fact-checking and consulted experts, these efforts remained intermittent and unenforced. Government responses were described as reactive, relying more on public credibility than legislation. Existing health legislation was seen as outdated, weakly enforced, and disconnected from digital realities. The COVID-19 pandemic exposed these vulnerabilities and highlighted the need for coordinated broadcasting approach and stronger expert oversight across media platforms. Medical misinformation in Lebanon is driven by structural weaknesses across media, health, and legal systems. Addressing it requires coordinated institutional action, improved health literacy, stronger collaboration between media and health professionals, and updated regulations suited to the digital era.

2 November 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LZLili Zeidan
Lili Zeidan
SKSarah Kamareddine
Sarah Kamareddine
MZMacy Zaatar
Macy Zaatar
MZMohamad Sadek Zoghbi
Mohamad Sadek Zoghbi
SHShahinda Hammoud
Shahinda Hammoud
EAElie Akl
Elie Akl
Background: During crises, both challenging circumstances and uncertainty threaten the continuity of research operations. Research projects, research institutions and funders need to implement strategies to ensure research continuity. Objective: To scope the literature on challenges to research continuity and strategies for ensuring research continuity during crises. Methods: We followed standard scoping review methodology and reported findings in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. We included quantitative, qualitative, and mixed-methods primary studies on our topic across all research disciplines and types of crises. We searched MEDLINE (OVID) and Scopus databases (January 2000 to January 2026). We abstracted data on study characteristics, challenges, mitigation strategies, and the role of funders. We summarized categorical data descriptively and analyzed qualitative data thematically presenting our findings in narrative and tabular formats. Results: Out of 22,002 captured citations, we identified 112 eligible studies. Most studies focused on pandemic-related crises (91%), mostly related to clinical research (47%) and social sciences (46%), and were conducted predominantly in high-income countries (80%). Challenges occurred at the project (81%), institutional (27%), and funder (15%) levels. The most common challenges for these levels were respectively project suspensions (58%), lack of institutional support (14%), and poor or no research funding (12%). Key mitigation strategies were flexible research operations (80%), adjustments to institutional policies and governance (25%), and implementing strategic interventions (31%). Funders contributed to research continuity, primarily through financial flexibility (56%) and supporting adaptations (39%). Conclusion: This scoping review maps the key challenges, strategies, and funder roles in sustaining research during crises. Findings highlight the need for flexible, resilient, and well-coordinated research systems across multiple levels. Future research should evaluate the long-term effectiveness of these strategies.

20 July 2026 in Surgery
Verified
Journal Article
Open access
MZMohamad Sadek Zoghbi
Mohamad Sadek Zoghbi
LHLama Hamade
Lama Hamade
DIDima Itani
Dima Itani
YZYomna El Zibaoui
Yomna El Zibaoui
MMMoustafa Moussally
Moustafa Moussally
EGEmre Gorgun
Emre Gorgun

17 September 2026 in Genes
Verified
Journal Article
Open access
PDF file
HEHadi Al Etri
Hadi Al Etri
LZLea Al Zoghby
Lea Al Zoghby
MZMohamad Sadek Zoghbi
Mohamad Sadek Zoghbi
AMAhmad Karim Morad
Ahmad Karim Morad
HHHatem Hassanein
Hatem Hassanein
Jad ChahoudJad Chahoud
Jad Chahoud
Therapeutic options in renal cell carcinoma (RCC) have expanded rapidly, including adjuvant pembrolizumab, HIF-2α-directed therapy, and multiple effective first-line combinations for metastatic clear-cell RCC (ccRCC), yet treatment selection remains largely clinicopathologic. This review evaluates biomarkers at three clinical decision points: characterization of an indeterminate renal mass; recurrence-risk assessment and adjuvant treatment selection after nephrectomy; and first-line regimen selection in metastatic ccRCC. DNA-methylation classifiers and carbonic anhydrase IX-targeted [89Zr]Zr-girentuximab PET/CT can improve characterization of selected renal tumors, but neither replaces histopathology in routine practice. After nephrectomy, elevated plasma kidney injury molecule-1 (KIM-1) and detectable circulating tumor DNA (ctDNA) identify patients at higher risk of recurrence; however, low tumor shedding limits ctDNA sensitivity, so a negative result does not exclude molecular residual disease or justify adjuvant de-escalation; neither biomarker is validated to direct surveillance, adjuvant therapy, or treatment escalation. In metastatic ccRCC, PD-L1 expression, tumor mutational burden, and individual genomic alterations do not reliably distinguish patients who should receive dual immune-checkpoint blockade from those who should receive an immune-checkpoint inhibitor plus a VEGFR tyrosine kinase inhibitor. Transcriptomic states, myeloid composition, and spatial immune organization provide more detailed treatment-relevant biology, but no prospective comparative trial has shown that biomarker-guided regimen selection improves outcomes. Clinical implementation will require standardized assays, independent multicenter validation, and prospective trials powered to test biomarker-by-treatment interactions.